Diabetic Macular Edema / Diabetic Retinopathy – Landscape & Forecast – Disease Landscape & Forecast (G7)

Diabetic macular edema (DME) is a complication of diabetic retinopathy (DR) derived from chronically high blood sugar levels, resulting in vision loss and blindness, if left untreated. The treatment landscape for DR and DME is evolving rapidly, with established anti-VEGF therapies like Eylea, Lucentis, and off-label Avastin remaining central to management. Additionally, the sustained-release corticosteroid implants Ozurdex and Iluvien provide alternative options. Since 2022, the market has seen increased competition with the launch of Vabysmo, Eylea HD, and Pavblu, the first biosimilar of Eylea, and the anticipated approval of AbbVie / Regenxbio’s ABBV-RGX-314 SCS and 4DMT’s 4D-150 represents a breakthrough in gene therapies for retinal diseases. Furthermore, non-intravitreal agents like Oculis’s OCS-01, a topical eye drop formulation, will likely constitute a paradigm shift and may revolutionize the treatment of DME patients in the future.

Questions answered

• How large are the treatable DR and DME populations, and how will diagnosis and drug-treatment rates change over time?
• What key differences do KOLs perceive between current IVT therapies? How is the use of these drugs expected to change over the next 10 years?
• How will DR and DME treatment algorithms change as innovative products like gene therapies and first-in-class agents launch?
• How will market dynamics be impacted by the launch of biosimilars of Eylea?

Product description

Disease Landscape & Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:

• Optimize your long-term disease and development strategy.
• Quantify market potential for your pipeline assets and those of your competitors.
• Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.
• Gauge the commercial outlook and impact of key market events.